Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential

Jason J. Kwon, Jeffrey A. Willy, Kayla A. Quirin, Ronald C. Wek, Murray Korc, Xiao Ming Yin, Janaiah Kota

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Pancreatic Ductal Adenocarcinoma (PDAC) is a highly lethal malignancy that responds poorly to current therapeutic modalities. In an effort to develop novel therapeutic strategies, we found downregulation of miR-29 in pancreatic cancer cells, and overexpression of miR-29a sensitized chemotherapeutic resistant pancreatic cancer cells to gemcitabine, reduced cancer cell viability, and increased cytotoxicity. Furthermore, miR-29a blocked autophagy flux, as evidenced by an accumulation of autophagosomes and autophagy markers, LC3B and p62, and a decrease in autophagosome-lysosome fusion. In addition, miR-29a decreased the expression of autophagy proteins, TFEB and ATG9A, which are critical for lysosomal function and autophagosome trafficking respectively. Knockdown of TFEB or ATG9A inhibited autophagy similar to miR-29a overexpression. Finally, miR-29a reduced cancer cell migration, invasion, and anchorage independent growth. Collectively, our findings indicate that miR-29a functions as a potent autophagy inhibitor, sensitizes cancer cells to gemcitabine, and decreases their invasive potential. Our data provides evidence for the use of miR-29a as a novel therapeutic agent to target PDAC.

Original languageEnglish (US)
Pages (from-to)71635-71650
Number of pages16
JournalOncotarget
Volume7
Issue number44
DOIs
StatePublished - Jan 1 2016

Keywords

  • Autophagy
  • Gemcitabine
  • Metastasis
  • Pancreatic cancer
  • miR-29

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential'. Together they form a unique fingerprint.

  • Cite this